131 related articles for article (PubMed ID: 25101855)
1. Differences in regional diagnostic strategies and in intended versus actual first-line treatment of patients with advanced ovarian cancer in Denmark.
Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Sogaard CH; Hoegdall C
Int J Gynecol Cancer; 2014 Sep; 24(7):1195-205. PubMed ID: 25101855
[TBL] [Abstract][Full Text] [Related]
2. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
[TBL] [Abstract][Full Text] [Related]
3. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
[TBL] [Abstract][Full Text] [Related]
4. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
5. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.
Cornelis S; Van Calster B; Amant F; Leunen K; van der Zee AG; Vergote I
Int J Gynecol Cancer; 2012 Mar; 22(3):407-16. PubMed ID: 22367320
[TBL] [Abstract][Full Text] [Related]
6. A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
Eoh KJ; Yoon JW; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
BMC Cancer; 2017 Jul; 17(1):481. PubMed ID: 28701190
[TBL] [Abstract][Full Text] [Related]
7. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
10. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
11. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
12. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
14. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
16. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
17. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?
Vizzielli G; Fanfani F; Chiantera V; Tortorella L; Lucidi A; Petrillo M; Costantini B; Scambia G; Fagotti A
Anticancer Res; 2015 May; 35(5):3027-32. PubMed ID: 25964591
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences.
Fagö-Olsen CL; Ottesen B; Kehlet H; Markauskas A; Mosgaard BJ; Ottosen C; Søgaard CH; Søgaard-Andersen E; Høgdall C
Dan Med J; 2012 Aug; 59(8):A4477. PubMed ID: 22849978
[TBL] [Abstract][Full Text] [Related]
20. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
Qin L; Huang H; Chen M; Liang Y; Wang H
J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
